Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer

Pancreatic cancer remains a clinical challenge, thus new therapies are urgently needed. The selective Wee1 inhibitor MK-1775 has demonstrated promising results when combined with DNA damaging agents, and more recently with CHK1 inhibitors in various malignancies. We have previously demonstrated that...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Lett
Главные авторы: Wang, Guan, Niu, Xiaojia, Zhang, Wenbo, Caldwell, J. Timothy, Edwards, Holly, Chen, Wei, Taub, Jeffrey W., Zhao, Lijing, Ge, Yubin
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4282784/
https://ncbi.nlm.nih.gov/pubmed/25458954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2014.10.015
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы